Fig. 1From: Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter studyMedian tofacitinib plasma concentration–time profiles for each cohort. aMean tofacitinib plasma concentration–time profile for adult patients who received tofacitinib 5 mg BID in a Phase 2 dose-ranging study in patients with active rheumatoid arthritis [20]. BID twice dailyBack to article page